- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2014
- Public Summary Document (PSD) November 2014 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2014 PBAC Meeting - Word
Aflibercept – November 2014
Aflibercept; 4 mg/0.1 mL injection, 1 x 0.1 mL vial, 4 mg/0.1 mL injection, 1 x 0.09 mL syringe; Eylea® (CRVO)
Last updated
6 March 2015